We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer’s Ibrance Breast Cancer Drug Nabs Accelerated Approval
Pfizer’s Ibrance Breast Cancer Drug Nabs Accelerated Approval
Pfizer’s novel breast cancer drug Ibrance shows reasonable evidence of clinical benefit to warrant marketing it ahead of a Phase III study, the FDA said in granting accelerated approval Tuesday.